Sfoglia per Autore
How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial
2014-01-01 Durelli, L.; De Mercanti, S.F.; Sormani, M.P.; Piazza, F.; Schiavetti, I.; Gned, D.; Brescia Morra, V.; Lanzillo, R.; Amato, L.; Quarantelli, M.; Ghezzi, A.; Bianchi, A.; Baroncini, D.; Salemi, G.; Realmuto, S.; Ferrò, M.T.; Vitetta, F.; Superti, G.; Cavalla, P.; D’Onghia, M.; Paolicelli, D.; Pinessi, L.; Trojano, M.; Clerico, M.
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study
2014-01-01 S De Mercanti ; M Clerico ; S Rolla ; V Bardina ; M.A Cucci ; D Taverna ; D Cimino ; F Piazza ; E Virgilio ; D Armocida ; M Basso ; A Vladic ; M Habek ; I Adamec ; V Brinar ; E Cocco ; J Frau ; P Annovazzi ; D Horàkovà ; I Kovàrovà ; F Novelli ; L Durelli
Epigenetic therapy for Friedreich ataxia.
2014-01-01 Soragni E;Miao W;Iudicello M;Jacoby D;De Mercanti S;Clerico M;Longo F;Piga A;Ku S;Campau E;Du J;Penalver P;Rai M;Madara JC;Nazor K;O'Connor M;Maximov A;Loring JF;Pandolfo M;Durelli L;Gottesfeld JM;Rusche JR
Natalizumab Therapy, How to Treat How to Stop: The TY-STOP Study
2014-01-01 Clerico, M.; De Mercanti, S.; Piazza, F.; Virgilio, E.; Gned, D.; Brescia Morra, V.; Lanzillo, R.; Amato, L.; Quarantelli, M.; Ghezzi, A.; Bianchi, A.; Baroncini, D.; Salemi, G.; Realmuto, S.; Ferrò, M.T.; Vitetta, F.; Superti, G.; Cavalla, P.; D'Onghia, M.; Paolicelli, D.; Schiavetti, I.; Sormani, M.P.; Pinessi, L.; Trojano, M.; Durelli, L.
Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP
2014-01-01 Clerico, M; Schiavetti, I; De Mercanti, Sf; Piazza, F; Gned, D; Brescia Morra, V; Lanzillo, R; Ghezzi, A; Bianchi, A; Salemi, G; Realmuto, S; Sola, P; Vitetta, F; Cavalla, P; Superti, G; Ferraro, D; Paolicelli, D; Trojano, M; Sormani, Mp; Durelli, L
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab
2014-01-01 Marinella Clerico;Irene Schiavetti;Stefania F. De Mercanti;Federico Piazza;Dario Gned;Vincenzo Brescia Morra;Roberta Lanzillo;Angelo Ghezzi;Anna Bianchi;Giuseppe Salemi;Sabrina Realmuto;Patrizia Sola;Francesca Vitetta;Paola Cavalla;Damiano Paolicelli;Maria Trojano;Maria Pia Sormani;Luca Durelli
Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes.
2014-01-01 Carvajal-González A;Leite MI;Waters P;Woodhall M;Coutinho E;Balint B;Lang B;Pettingill P;Carr A;Sheerin UM;Press R;Lunn MP;Lim M;Maddison P;Meinck HM;Vandenberghe W;Vincent A; Glycine receptor antibody study group; Durelli L. included as part of Glycine receptor antibody study group
Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study
2013-01-01 De Mercanti S; Clerico M; Rolla S; Cucci A; Novelli F; Taverna D; Bardina V; Piazza F; Gibbin M; Vargas J; Vladic A; Habek M; Adamec B; Brinar V; Cocco E; Frau J; Annovazzi P; Horakova D; Kovarova I; Durelli L
Atypical presentation of superficial sclerosis successfully treated with iron chelation
2013-01-01 De Mercanti S; Iudicello M; Clerico M; Piazza F; Gibbin M; Longo F; Durelli L
Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.
2013-01-01 Patti F;Morra VB;Amato MP;Trojano M;Bastianello S;Tola MR;Cottone S;Plant A;Picconi O;COGIMUS Study Group; Durelli L. as member of COGIMUS Study Group
Role of Th22 expansion in multiple sclerosis disease activity
2013-01-01 De Mercanti S; Clerico M; Rolla S; Bardina V; Quaglino P; De Palma R; Gned D; Novelli F; Durelli L
Natalizumab discontinuation after the 24th course: which is the way? The TY-STOP study
2013-01-01 Clerico M; De Mercanti S; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Amato L; Quarantelli M; Ghezzi A; Bianchi A; Baroncini D; Gibbin M; Vargas J; Salemi G; Realmuto S; Ferro MT; Vitetta F; Sola P; Paolicelli D; Trojano M; Durelli L
Management of multiple sclerosis patients after the 24th Natalizumab course: the Ty-STOP study
2013-01-01 Clerico M; De Mercanti S; Versino E; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Amato R; Quarantelli M; Ghezzi A; Bianchi A; Baroncini D; Salemi G; Realmuto S; Ferro MT; Vitetta F; Donghia M; Paolicelli D; Trojano M; Durelli L
Phenotypical and functional characterization of T Helper 22 cells inMultiple Sclerosis patients
2012-01-01 S. Rolla; M. Clerico; V. Bardina; P. Quaglino; L. Durelli; F. Novelli
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
2012-01-01 Lugaresi A;Florio C;Brescia-Morra V;Cottone S;Bellantonio P;Clerico M;Centonze D;Uccelli A;di Ioia M;De Luca G;Marcellusi A;Paolillo A;for the BRIDGE study group
Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course
2012-01-01 Cook, Sd; Dhib-Jalbut, S; Dowling, P; Durelli, L; Ford, C; Giovannoni, G; Halper, J; Harris, C; Herbert, J; Li, D; Lincoln, Ja; Lisak, R; Lublin, Fd; Lucchinetti, Cf; Moore, W; Naismith, Rt; Oehninger, C; Simon, J; Sormani, Mp.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
2012-01-01 Alasdair J Coles,Cary L Twyman,Douglas L Arnold,Jeffrey A Cohen,Christian Confavreux,Edward J Fox,Hans-Peter Hartung,Eva Havrdova,Krzysztof W Selmaj,Howard L Weiner,Tamara Miller,Elizabeth Fisher,Rupert Sandbrink,Stephen L Lake,David H Margolin,Pedro Oyuela,Michael A Panzara,D Alastair S Compston, and the CARE-MS II investigators: Ajay S. Gupta, Edward Fox, Steven A. Glyman, Timothy K. Thoits, Herman C. Sullivan, Mark C. Cascione, Kottil W. Rammohan, Suzanne K. Gazda, Daniel R. Wynn, Sibyl E. Wray, Stanton Elias, Corey C. Ford, Andrew Goodman, Bruce L. Hughes; Omar Azhar Khan, Anand G. Vaishnav, Stephen Kirzinger, Sharon G. Lynch, David H. Mattson, Tiffany J. Braley, Daniel D. Mikol, Stephen Krieger, Tamara Ann Miller, Peter N. Riskind, Roberto Bomprezzi, Dean M. Wingerchuk, Brian Steingo, Jeffrey Alan Cohen, Heidi J. Crayton, Cary L. Twyman, Joanna A. Cooper, Leslie P. Weiner, Harold Moses Jr., Mark A. Agius, Ann Doan-Do Bass, Enrico C. Lallana, Galen W. Mitchell, Stanley J. Krolczyk, Alireza Minagar, Burk Jubelt, Bradley K. Evans, Samuel F. Hunter, Syed A. Rizvi, Christopher A. Sheppard, WM. David Honeycutt, Joseph Herbert, Ellen S. Lathi, Gabriel Pardo, Lily Jung Ilenson, Ted L. Rothstein, Ben W. Thrower, Mary Ann Picone, Mariko Kita, Erica M. Grazioli, Scott L. Silliman, Thomas Giancarlo, Malcolm H. Gottesman, Nuhad E. Abou Zeid, Vernon D. Rowe, Christine M. Boutwell, John D. Schaeffer, Claire S Riley, Keith R. Edwards, Jeanette K. Wendt, G. Kim Bigley Jr., Richard A. Shubin, Silva Markovic-Plese, Davis E. Jones, Gary Clauser, Mark S. Freedman, Francois Grand’Maison, Francois H. Jacques, Anthony L. Traboulsee, Donald G. Brunet, Marcelo Kremenchutzky, Charles Ayotte, Neil S. Lava, Stephen R. Waldman, Todd J. Janus, Stephen Gerard Vincent, Mark Gudesblatt, Michael Rossen, Lee S. Stein, Bennett-Irving Machanic, Timothy Vollmer, Jeffrey S. Gitt, Jeffrey Dunn, Donald Negroski, Mark H. Fletcher, Adil Javed, Elliot M. Frohman, Richard Macdonell, John Owen King, Mark A. Paine, Karyn Boundy, Simon Broadley, Steve Vucic, Stephen Reddel, Michael D. Dreyer, Raymond Schwartz, Pamela Ann McCombe, Suzanne Hodgkinson, Charles Tilbery, Maria Lucia B. Ferreira, Dagoberto Callegaro, Marcio Mena Barreto Martins, Jesus Arturo Violante Villanueva, Noemi Santos Caballero, Claudia Venzor Mendoza, Norma Haydee Deri, Alasdair Coles, Neil James Scolding, Gavin Giovannoni, Basil Sharrack, David J. Rog, Giancarlo Comi, Angelo Ghezzi, MD, Giovanni L. Mancardi, Luca Durelli, Antonio Bertolotto, Ruggero Capra, Carlo Pozzilli, Maria Giovanna Marrosu, Raymond M. M. Hupperts, Erik van Munster, Xavier Montalbán, Rafael Arroyo González, Guillermo Izquierdo Ayuso, Óscar Fernández Fernández, Christian Confavreux, Patrick Vermersch, Jerome de Seze, Thibault Moreau, Pierre Clavelou, Catherine Lubetzki, Michel Clanet, Marc Debouverie, Gilles Edan, Hans-Peter Hartung, Judith Haas, Martin Stangel, Tjalf Ziemssen, Bernhard Hemmer, Karl Baum, U. Klaus Zettl, U. Herrlinger, Wolfgang Köhler, Gunter Ochs, Patrick Oschmann, Klaus Tiel-Wilck, Hayrettin Tumani, Peter P. Urban, Jan Lycke, Anders Svenningsson, Ivana Kovarova, Marta Vachova, Ivan Rektor, Radomir Talab, Krzysztof Selmaj, Zbigniew Stelmasiak, Wojciech Kozubski, Benedicte D. P. Dubois, Dominique Dive, Christian Sindic, Karl Vass, Per Soelberg Sørensen, Thor Petersen, Mads Ravnborg, Anat Achiron, Adi Vaknin Dembinsky, Arnon Karni, Evgeny I. Gusev, Igor D. Stolyarov, Igor A. Zavalishin, Alexander A. Skoromets, Alexei N. Boyko, Anna N. Belova, Nadezhda A. Malkova, Evgeniy R. Barantsevich, Eduard Z. Yakupov, Semen V. Perfiliev, Irina E. Poverennova, Natalia P. Voloshyna, Tetyana I. Nehrych, Tetyana O. Kobys, Mario Habek, Vesna Brinar, Zlatko Trkanjec, Anton Vladić, Spomenka Kidemet Piskać, Licia Antonelli, Jelena Drulović, Čongor Nadj, Evica Dinčić, Gordana Tončev
T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials
2012-01-01 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Kovarova,I.; Clerico, M.; Durelli, L.
Th17 Cells in Multiple Sclerosis Express Higher Levels of JAK2, Which Increases Their Surface Expression of IFN-γR2
2012-01-01 Conti L; De Palma R; Rolla S; Boselli D; Rodolico G; Kaur S; Silvennoinen O; Niccolai E; Amedei A; Ivaldi F; Clerico M; Contessa G; Uccelli A; Durelli L; Novelli F.
Multiparametric analysis of Th17 and Th22 cells discloses their pathogenicity in human multiple sclerosis
2012-01-01 Rolla, S.; Bardina, V.; Clerico, M.; Durelli L. and Novelli F.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial | 2014 | Durelli, L.; De Mercanti, S.F.; Sormani, M.P.; Piazza, F.; Schiavetti, I.; Gned, D.; Brescia Morra, V.; Lanzillo, R.; Amato, L.; Quarantelli, M.; Ghezzi, A.; Bianchi, A.; Baroncini, D.; Salemi, G.; Realmuto, S.; Ferrò, M.T.; Vitetta, F.; Superti, G.; Cavalla, P.; D’Onghia, M.; Paolicelli, D.; Pinessi, L.; Trojano, M.; Clerico, M. | |
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study | 2014 | S De Mercanti ; M Clerico ; S Rolla ; V Bardina ; M.A Cucci ; D Taverna ; D Cimino ; F Piazza ; E Virgilio ; D Armocida ; M Basso ; A Vladic ; M Habek ; I Adamec ; V Brinar ; E Cocco ; J Frau ; P Annovazzi ; D Horàkovà ; I Kovàrovà ; F Novelli ; L Durelli | |
Epigenetic therapy for Friedreich ataxia. | 2014 | Soragni E;Miao W;Iudicello M;Jacoby D;De Mercanti S;Clerico M;Longo F;Piga A;Ku S;Campau E;Du J;Penalver P;Rai M;Madara JC;Nazor K;O'Connor M;Maximov A;Loring JF;Pandolfo M;Durelli L;Gottesfeld JM;Rusche JR | |
Natalizumab Therapy, How to Treat How to Stop: The TY-STOP Study | 2014 | Clerico, M.; De Mercanti, S.; Piazza, F.; Virgilio, E.; Gned, D.; Brescia Morra, V.; Lanzillo, R.; Amato, L.; Quarantelli, M.; Ghezzi, A.; Bianchi, A.; Baroncini, D.; Salemi, G.; Realmuto, S.; Ferrò, M.T.; Vitetta, F.; Superti, G.; Cavalla, P.; D'Onghia, M.; Paolicelli, D.; Schiavetti, I.; Sormani, M.P.; Pinessi, L.; Trojano, M.; Durelli, L. | |
Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP | 2014 | Clerico, M; Schiavetti, I; De Mercanti, Sf; Piazza, F; Gned, D; Brescia Morra, V; Lanzillo, R; Ghezzi, A; Bianchi, A; Salemi, G; Realmuto, S; Sola, P; Vitetta, F; Cavalla, P; Superti, G; Ferraro, D; Paolicelli, D; Trojano, M; Sormani, Mp; Durelli, L | |
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab | 2014 | Marinella Clerico;Irene Schiavetti;Stefania F. De Mercanti;Federico Piazza;Dario Gned;Vincenzo Brescia Morra;Roberta Lanzillo;Angelo Ghezzi;Anna Bianchi;Giuseppe Salemi;Sabrina Realmuto;Patrizia Sola;Francesca Vitetta;Paola Cavalla;Damiano Paolicelli;Maria Trojano;Maria Pia Sormani;Luca Durelli | |
Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. | 2014 | Carvajal-González A;Leite MI;Waters P;Woodhall M;Coutinho E;Balint B;Lang B;Pettingill P;Carr A;Sheerin UM;Press R;Lunn MP;Lim M;Maddison P;Meinck HM;Vandenberghe W;Vincent A; Glycine receptor antibody study group; Durelli L. included as part of Glycine receptor antibody study group | |
Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study | 2013 | De Mercanti S; Clerico M; Rolla S; Cucci A; Novelli F; Taverna D; Bardina V; Piazza F; Gibbin M; Vargas J; Vladic A; Habek M; Adamec B; Brinar V; Cocco E; Frau J; Annovazzi P; Horakova D; Kovarova I; Durelli L | |
Atypical presentation of superficial sclerosis successfully treated with iron chelation | 2013 | De Mercanti S; Iudicello M; Clerico M; Piazza F; Gibbin M; Longo F; Durelli L | |
Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. | 2013 | Patti F;Morra VB;Amato MP;Trojano M;Bastianello S;Tola MR;Cottone S;Plant A;Picconi O;COGIMUS Study Group; Durelli L. as member of COGIMUS Study Group | |
Role of Th22 expansion in multiple sclerosis disease activity | 2013 | De Mercanti S; Clerico M; Rolla S; Bardina V; Quaglino P; De Palma R; Gned D; Novelli F; Durelli L | |
Natalizumab discontinuation after the 24th course: which is the way? The TY-STOP study | 2013 | Clerico M; De Mercanti S; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Amato L; Quarantelli M; Ghezzi A; Bianchi A; Baroncini D; Gibbin M; Vargas J; Salemi G; Realmuto S; Ferro MT; Vitetta F; Sola P; Paolicelli D; Trojano M; Durelli L | |
Management of multiple sclerosis patients after the 24th Natalizumab course: the Ty-STOP study | 2013 | Clerico M; De Mercanti S; Versino E; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Amato R; Quarantelli M; Ghezzi A; Bianchi A; Baroncini D; Salemi G; Realmuto S; Ferro MT; Vitetta F; Donghia M; Paolicelli D; Trojano M; Durelli L | |
Phenotypical and functional characterization of T Helper 22 cells inMultiple Sclerosis patients | 2012 | S. Rolla; M. Clerico; V. Bardina; P. Quaglino; L. Durelli; F. Novelli | |
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. | 2012 | Lugaresi A;Florio C;Brescia-Morra V;Cottone S;Bellantonio P;Clerico M;Centonze D;Uccelli A;di Ioia M;De Luca G;Marcellusi A;Paolillo A;for the BRIDGE study group | |
Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course | 2012 | Cook, Sd; Dhib-Jalbut, S; Dowling, P; Durelli, L; Ford, C; Giovannoni, G; Halper, J; Harris, C; Herbert, J; Li, D; Lincoln, Ja; Lisak, R; Lublin, Fd; Lucchinetti, Cf; Moore, W; Naismith, Rt; Oehninger, C; Simon, J; Sormani, Mp. | |
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial | 2012 | Alasdair J Coles,Cary L Twyman,Douglas L Arnold,Jeffrey A Cohen,Christian Confavreux,Edward J Fox,Hans-Peter Hartung,Eva Havrdova,Krzysztof W Selmaj,Howard L Weiner,Tamara Miller,Elizabeth Fisher,Rupert Sandbrink,Stephen L Lake,David H Margolin,Pedro Oyuela,Michael A Panzara,D Alastair S Compston, and the CARE-MS II investigators: Ajay S. Gupta, Edward Fox, Steven A. Glyman, Timothy K. Thoits, Herman C. Sullivan, Mark C. Cascione, Kottil W. Rammohan, Suzanne K. Gazda, Daniel R. Wynn, Sibyl E. Wray, Stanton Elias, Corey C. Ford, Andrew Goodman, Bruce L. Hughes; Omar Azhar Khan, Anand G. Vaishnav, Stephen Kirzinger, Sharon G. Lynch, David H. Mattson, Tiffany J. Braley, Daniel D. Mikol, Stephen Krieger, Tamara Ann Miller, Peter N. Riskind, Roberto Bomprezzi, Dean M. Wingerchuk, Brian Steingo, Jeffrey Alan Cohen, Heidi J. Crayton, Cary L. Twyman, Joanna A. Cooper, Leslie P. Weiner, Harold Moses Jr., Mark A. Agius, Ann Doan-Do Bass, Enrico C. Lallana, Galen W. Mitchell, Stanley J. Krolczyk, Alireza Minagar, Burk Jubelt, Bradley K. Evans, Samuel F. Hunter, Syed A. Rizvi, Christopher A. Sheppard, WM. David Honeycutt, Joseph Herbert, Ellen S. Lathi, Gabriel Pardo, Lily Jung Ilenson, Ted L. Rothstein, Ben W. Thrower, Mary Ann Picone, Mariko Kita, Erica M. Grazioli, Scott L. Silliman, Thomas Giancarlo, Malcolm H. Gottesman, Nuhad E. Abou Zeid, Vernon D. Rowe, Christine M. Boutwell, John D. Schaeffer, Claire S Riley, Keith R. Edwards, Jeanette K. Wendt, G. Kim Bigley Jr., Richard A. Shubin, Silva Markovic-Plese, Davis E. Jones, Gary Clauser, Mark S. Freedman, Francois Grand’Maison, Francois H. Jacques, Anthony L. Traboulsee, Donald G. Brunet, Marcelo Kremenchutzky, Charles Ayotte, Neil S. Lava, Stephen R. Waldman, Todd J. Janus, Stephen Gerard Vincent, Mark Gudesblatt, Michael Rossen, Lee S. Stein, Bennett-Irving Machanic, Timothy Vollmer, Jeffrey S. Gitt, Jeffrey Dunn, Donald Negroski, Mark H. Fletcher, Adil Javed, Elliot M. Frohman, Richard Macdonell, John Owen King, Mark A. Paine, Karyn Boundy, Simon Broadley, Steve Vucic, Stephen Reddel, Michael D. Dreyer, Raymond Schwartz, Pamela Ann McCombe, Suzanne Hodgkinson, Charles Tilbery, Maria Lucia B. Ferreira, Dagoberto Callegaro, Marcio Mena Barreto Martins, Jesus Arturo Violante Villanueva, Noemi Santos Caballero, Claudia Venzor Mendoza, Norma Haydee Deri, Alasdair Coles, Neil James Scolding, Gavin Giovannoni, Basil Sharrack, David J. Rog, Giancarlo Comi, Angelo Ghezzi, MD, Giovanni L. Mancardi, Luca Durelli, Antonio Bertolotto, Ruggero Capra, Carlo Pozzilli, Maria Giovanna Marrosu, Raymond M. M. Hupperts, Erik van Munster, Xavier Montalbán, Rafael Arroyo González, Guillermo Izquierdo Ayuso, Óscar Fernández Fernández, Christian Confavreux, Patrick Vermersch, Jerome de Seze, Thibault Moreau, Pierre Clavelou, Catherine Lubetzki, Michel Clanet, Marc Debouverie, Gilles Edan, Hans-Peter Hartung, Judith Haas, Martin Stangel, Tjalf Ziemssen, Bernhard Hemmer, Karl Baum, U. Klaus Zettl, U. Herrlinger, Wolfgang Köhler, Gunter Ochs, Patrick Oschmann, Klaus Tiel-Wilck, Hayrettin Tumani, Peter P. Urban, Jan Lycke, Anders Svenningsson, Ivana Kovarova, Marta Vachova, Ivan Rektor, Radomir Talab, Krzysztof Selmaj, Zbigniew Stelmasiak, Wojciech Kozubski, Benedicte D. P. Dubois, Dominique Dive, Christian Sindic, Karl Vass, Per Soelberg Sørensen, Thor Petersen, Mads Ravnborg, Anat Achiron, Adi Vaknin Dembinsky, Arnon Karni, Evgeny I. Gusev, Igor D. Stolyarov, Igor A. Zavalishin, Alexander A. Skoromets, Alexei N. Boyko, Anna N. Belova, Nadezhda A. Malkova, Evgeniy R. Barantsevich, Eduard Z. Yakupov, Semen V. Perfiliev, Irina E. Poverennova, Natalia P. Voloshyna, Tetyana I. Nehrych, Tetyana O. Kobys, Mario Habek, Vesna Brinar, Zlatko Trkanjec, Anton Vladić, Spomenka Kidemet Piskać, Licia Antonelli, Jelena Drulović, Čongor Nadj, Evica Dinčić, Gordana Tončev | |
T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials | 2012 | De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Kovarova,I.; Clerico, M.; Durelli, L. | |
Th17 Cells in Multiple Sclerosis Express Higher Levels of JAK2, Which Increases Their Surface Expression of IFN-γR2 | 2012 | Conti L; De Palma R; Rolla S; Boselli D; Rodolico G; Kaur S; Silvennoinen O; Niccolai E; Amedei A; Ivaldi F; Clerico M; Contessa G; Uccelli A; Durelli L; Novelli F. | |
Multiparametric analysis of Th17 and Th22 cells discloses their pathogenicity in human multiple sclerosis | 2012 | Rolla, S.; Bardina, V.; Clerico, M.; Durelli L. and Novelli F. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile